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Protocol
AbstrACt
Purpose The purpose of this study is to compare the 
efficacy and safety of intravitreal aflibercept (IVA) with 
sham photodynamic therapy (sPDT) versus IVA with 
verteporfin PDT (vPDT) in a Caucasian population with 
treatment-naive polypoidal choroidal vasculopathy (PCV), 
enrolling into a treat and extend (T&E) regimen.
Methods and analysis Randomised, double-masked, 
sham-controlled, multicentre phase 4 investigator-driven 
clinical trial. The primary outcomes are (1) change in 
best-corrected visual acuity (BCVA) from baseline and (2) 
polyp regression at week 52, assessed by indocyanine 
green angiography (ICGA). Fifty patients with treatment-
naive PCV will be recruited from Portuguese and Spanish 
clinical sites. Eligible patients will receive monthly IVA 
for 3 months (week 0, week 4 and week 8). At week 
16, all patients will repeat ICGA and undergo central 
randomisation (1:1 ratio) into one of the following groups: 
Group 1—IVA T&E + vPDT; Group 2—IVA T&E + sPDT. PDT 
will be performed at week 16, week 28 and week 40 in 
the presence of active polyps. After week 16, the presence 
of macular fluid on optical coherence tomography will 
determine the schedule of observations. When present, the 
interval between visits/injections will decrease 2 weeks 
(minimum 6 weeks). When not, the interval between visits/
injections will increase 2 weeks (maximum 12 weeks). 
Efficacy will be evaluated based on BCVA, central retinal 
thickness and polyp regression. Safety parameters will 
include assessment of intraocular pressure, adverse 
events and serious adverse events.
Ethics and dissemination This study was designed 
and shall be implemented and reported in accordance 
with the International Conference on Harmonisation (ICH) 
Harmonised Tripartite Guidelines for Good Clinical Practice, 
with applicable local regulations and with the ethical 
principles laid down in the Declaration of Helsinki. The 
study received approval from Comissão de Ética para a 
Investigação Clínica and Comité Ético de investigación 
Clínica del Hospital Universitari de Bellvitge.
trial registration number This study is registered 
under the EudraCT number: 2015-001368-20 and the  
ClinicalTrials. gov Identifier: NCT02495181.
IntroduCtIon
Polypoidal choroidal vasculopathy (PCV) 
is an increasingly recognised neovascular 
phenotype of age-related macular degen-
eration (AMD), representing up to 13% of 
choroidal neovascularisation (CNV) cases in 
Caucasians and up to 50% in Asians.1 2 While 
PCV and typical exudative AMD share some 
clinical features and risk factors, differences 
regarding the genetic background, epidemi-
ological characteristics, natural history and 
treatment outcomes point to distinct patho-
physiological processes.1 3 4 The intravitreal 
strengths and limitations of this study
 ► First randomised clinical trial in a Caucasian 
population conducted to evaluate the safety and 
efficacy of aflibercept in polypoidal choroidal 
vasculopathy, either alone or in combination with 
photodynamic therapy.
 ► Multicentre, double-masked, sham-controlled 
clinical trial.
 ► Since it is mainly a proof of concept study with a 
relatively small study population, further validation 
of its main results will be needed.
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injection of antivascular endothelial growth factor (anti-
VEGF) is now the mainstay of treatment of wet AMD. 
However, the use of anti-VEGF compounds in mono-
therapy in PCV has been associated with a lower rate of 
polyp closure, despite the good visual outcomes. In the 
EVEREST study,5 a 6-month multicentre, randomised 
clinical trial (RCT) conducted to evaluate the efficacy 
and safety of verteporfin photodynamic therapy (vPDT) 
with or without 0.5 mg ranibizumab versus ranibizumab 
0.5 mg monotherapy in Asian patients with symptomatic 
PCV, the authors reported a significantly lower rate of 
complete polyp regression in the ranibizumab mono-
therapy group (28.6%) than in the PDT-containing 
treatment arms (77.8% in the PDT plus ranibizumab arm 
and 71.4% in the PDT monotherapy arm). All treatment 
arms showed an improvement of best-corrected visual 
acuity (BCVA) from baseline, with patients in the combi-
nation group achieving the highest gain (+10.9 letters 
from baseline). The proportion of patients gaining ≥15 
letters was 21% in the vPDT + ranibizumab group, 19% 
in the vPDT group and 33.3% in the ranibizumab mono-
therapy group. However, BCVA differences between 
groups were not statistically significant. Another study in 
an Asian population, the LAPTOP study,6 7 randomised 
patients with PCV to either ranibizumab monotherapy or 
PDT monotherapy. A higher proportion of patients in the 
ranibizumab arm gained 0.2 logMAR than those in the 
PDT arm, both at 12 and 24 months. Nevertheless, the 
polyp regression rate was not evaluated. In 2013, a group of 
experts published a set of guidelines for the management 
of PCV8 and recommended a combination of indocyanine 
green angiography (ICGA) guided PDT with Verteporfin 
and 3 monthly injections of ranibizumab 0.5 mg as the 
initial treatment of active juxtafoveal and subfoveal PCV. 
A systematic review and meta-analysis published by Wang 
et al9 concluded that even though combined treatment 
(PDT + ranibizumab 0.5 mg) appeared to result in better 
visual acuity and lower retinal haemorrhage, it did not 
affect the resolution and recurrence of lesions.
Given the introduction of aflibercept in clinical prac-
tice and its promising results in typical exudative AMD,10 
clarifying its anatomical and functional outcomes in the 
treatment of PCV, either alone or in combination with 
PDT, is an unmet medical need. Previously known as VEGF 
trap-eye,11 aflibercept (Eylea, Regeneron Pharmaceuti-
cals, Tarrytown, New York, USA) is a chimeric molecule 
composed of an Fc fragment linked to the extracellular 
portions of the VEGFR1 and VEGFR2 receptors. It binds 
to all isoforms of VEGF, thus preventing activation of VEGF 
receptors.12 The approved treatment regimen for wet AMD 
is one injection per month for three consecutive months, 
followed by one injection every 2 months (2 mg every 8 
weeks—2Q8). Kikushima et al13 retrospectively evaluated 
the results of aflibercept monotherapy versus a combined 
regimen of aflibercept and PDT in an Asian population 
with PCV. The authors reported that the combined treat-
ment might be superior to aflibercept monotherapy in 
terms of disease-stabilising efficacy, but with an equivalent 
visual gain at 12 months.13 However, to the best of our 
knowledge, no RCT has been conducted in Caucasians to 
evaluate the safety and efficacy of aflibercept in PCV, either 
alone or in combination with PDT. Considering that several 
genetic variants associated with PCV do not seem to trans-
late across ethnic lines,3 14–16 it is important as a proof of 
concept to evaluate if a combination regimen is superior to 
anti-VEGF monotherapy in the specific setting of a Cauca-
sian population. There is also some controversy regarding 
the real need of closuring all the polyps when treating PCV. 
In fact, based on the visual acuity results of the EVEREST 
study,5 many ophthalmologists are currently treating PCV 
with anti-VEGF monotherapy. A treat and extend (T&E) 
regimen using aflibercept with or without PDT may answer 
these questions, eventually leading to a paradigm shift in the 
current management of PCV. The importance of this study 
lies in the possibility of providing responses to the following 
questions: (1) is aflibercept safe when used in combina-
tion with PDT? (2) can combination therapy of aflibercept 
plus PDT improve the anatomical and functional results in 
PCV when compared with aflibercept monotherapy? (3) is 
the currently approved aflibercept treatment regimen for 
typical exudative AMD effective in PCV? (4) what is the best 
injection interval for aflibercept in PCV eyes?
The primary objective of this study is to compare the 
efficacy and safety of intravitreal aflibercept (IVA) with 
sham PDT (sPDT) versus IVA with vPDT in a Caucasian 
population with treatment-naive PCV, undergoing a T&E 
regimen.
MEthods And AnAlysIs
Study type and study design 
Randomised, double-masked, sham-controlled, 
multicentre phase 4 investigator-driven clinical trial 
registered under the EudraCT number: 2015-001368-20 
and the  ClinicalTrials. gov Identifier: NCT02495181 
(see online supplementary file 1).
Study title
A randomised, double-masked, sham-controlled phase 4 
study of the efficacy, safety and tolerability of intravitreal 
aflibercept monotherapy compared with aflibercept with 
adjunctive photodynamic therapy in patients with polyp-
oidal choroidal vasculopathy
Study acronym
ATLANTIC
Sponsor
AIBILI—Association for Innovation and Biomedical 
Research on Light and Image
Contact name: Sandrina Nunes
Address: Azinhaga de Santa Comba, Celas, 3000–548 
Coimbra, Portugal
Tel: +351 289 480 137
Email:  4c@ aibili. pt
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Principal investigator
Rufino Silva MD, PhD
Central Reading Centre
Coimbra Ophthalmology Reading Centre (CORC)
 EVICR. net Coordinating Centre
AIBILI– EVICR. net Coordinating Centre
Study outcomes 
Primary outcomes
The primary outcomes of the study are:
1. Change in BCVA from baseline to week 52
2. Polyp regression at week 52, assessed by ICGA
Secondary outcomes
The secondary outcomes of the study are:
1. Change in BCVA over time
2. Change in BCVA at week 16
3. BCVA gain ≥5, 10 or 15 ETDRS (Early Treatment 
Diabetic Retinopathy Study) letters at week 52
4. BCVA loss ≥5, 10, 15 or 30 ETDRS letters at week 52
5. BCVA stabilisation at week 52 (BCVA change 
from baseline between −5 and +5 ETDRS letters, 
exclusively)
6. Polyp regression at week 16, assessed by ICGA
7. Complete polyp regression at week 52, assessed by 
ICGA
8. Complete polyp regression at week 16, assessed by 
ICGA
9. Presence of active polyps at week 52, assessed by ICGA
10. Presence of active polyps at week 16, assessed by ICGA
11. Presence of leakage on fluorescein angiography (FA) 
at week 52
12. Change in the central retinal thickness (CRT) over 
time (assessed by spectral domain optical coherence 
tomography (SD-OCT)
13. Presence of macular fluid at week 52 (assessed by SD-
OCT)
14. Total number of intravitreal injections of aflibercept
15. Total number of treatments with vPDT
16. Frequency and severity of ocular and non-ocular 
adverse events (AEs) over time
Outcome definitions
 ► BCVA will be determined according to the ETDRS 
protocol in all visits
 ► Polyp regression will be defined as a reduction in the 
total area of polyps, quantitatively assessed by certified 
graders of the Central Reading Centre
 ► Complete polyp regression will be defined as polyp 
inactivity/disappearance, assessed by ICGA
 ► Polyp activity will be defined as the presence of sin-
gle or multiple (cluster or string) hyperfluorescent 
round/oval lesions on ICGA, within the first 6 min af-
ter injection, with one or more of the following char-
acteristics
 – Nodular appearance on stereoscopic view of ICGA
 – Hypofluorescent halo surrounding the focal 
hyperfluorescent lesion(s) on early frames
 – Pulsatile filling of the lesion
 – Leakage in the late frames
 ► Polyp inactivity (of the polyps that remain visible) will 
be defined by an hypofluorescent lesion core in the 
ICGA late phases (washout of the dye), producing a 
ring-like staining of the polypoidal lesion(s) but with-
out associated leakage
Efficacy assessment
Efficacy will be assessed based on the following parame-
ters: BCVA, SD-OCT parameters (including the presence 
of intraretinal or subretinal fluid, the CRT variation and 
so on) and polyp regression (evaluated by ICGA).
Safety assessment
Safety parameters will include assessment of intraocular 
pressure (IOP), AEs and serious adverse events (SAEs).
Timelines
 ► Competitive recruitment started in November 2015
 ► Patient follow-up: 1 year after inclusion
Sample selection
The study population will consist of male and female 
subjects older than 50 years with treatment-naive PCV. 
Each investigator will recruit patients from his/her 
clinical practice, from approximately 20 clinical sites in 
Portugal and Spain. A total number of 50 subjects are 
expected to be enrolled in the study.
Eligibility criteria
Both eyes will be assessed at the screening visit for eligi-
bility and only one eye will be selected from each subject 
as the study eye. Subjects who sign the informed consent 
form will participate in a screening period (maximum 
21 days) to confirm eligibility by the Central Reading 
Centre—CORC. In case both eyes meet the eligibility 
criteria, the study eye will be the one with the worst BCVA.
Inclusion criteria
1. Age≥50.
2. Either gender.
3.  Patients with Treatment-naive PCV.
4. BCVA at study entry from 25 to 80 ETDRS letters 
(Snellen Equivalent 20/320 to 20/25)
5. Presence of PCV in the study eye assessed by the 
Central Reading Centre based on multimodal retinal 
imaging (colour fundus photography (CFP), SD-
OCT, FA and ICGA), including the presence of 
active polyps on ICGA, with or without branching 
vascular network (BVN). Subfoveal involvement is 
required, with intraretinal or subretinal fluid and/
or subfoveal pigment epithelium detachment( PED) 
seen on SD-OCT.
6. Greatest linear dimension (GLD) of the lesion on FA 
and ICGA ≤5400 µm. Using the Heidelberg software, 
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the total lesion is outlined manually, encompassing 
the BVN as well as all the polyps and any type 2 CNV 
component. The best-fit circle is then manually drawn 
around the total lesion outline. The circle’s diameter 
is used as the GLD of the lesion.
7. Women must be postmenopausal for at least 12 
months prior to trial entry, or surgically sterile, or 
in case of childbearing potential, women must be 
using highly effective method of birth control (ie, 
one that results in a failure rate less than 1% per 
year when used consistently and correctly, such as 
combined hormonal contraception, progestogen-
only hormonal contraception, intrauterine devices, 
intrauterine hormone-releasing system, bilateral 
tubal occlusion, vasectomised partner and sexual 
abstinence).
8. Ability to provide written informed consent.
9. Ability to return for all study visits.
Exclusion criteria
1. Active ocular or periocular infection or inflammation 
in the study eye.
2. Uncontrolled IOP in the study eye.
3. Ocular condition in the study eye likely to 
impact vision and confound study outcomes (eg, 
vitreomacular traction, epiretinal membrane with 
severe retinal folds, ocular inflammation, retinal 
vascular diseases like diabetic retinopathy or diabetic 
macular oedema).
4. Presence of centromacular scarring or atrophy 
indicating irreversible BCVA loss.
5. Prior treatment of the study eye with any anti-VEGF 
agents.
6. Systemic use of anti-VEGF products within 3 months 
prior to the study entry.
7. Previous intraocular surgery, macular laser treatment, 
PDT or intraocular steroids in the study eye.
8. Known serious allergies or history of hypersensitivity 
to fluorescein, indocyanine green, verteporfin or 
components used on Eylea formulation.
9. Subject with a condition (such as advanced, severe 
or unstable disease or its treatment) or subject in a 
situation which may put him/her at significant risk, 
confound the study results or significantly interfere 
with the subject’s participation in the study.
10. History of porphyria and clinically relevant 
impairment of liver function.
Patient withdrawal
Study medication must be discontinued and the subject 
withdrawn from the trial if the investigator determines 
that continuing it would result in a significant safety risk 
for that subject. The following circumstances require 
study discontinuation:
 ► Loss ≥15 ETDRS letters of BCVA from baseline.
 ► Withdrawal of informed consent.
 ► Any other protocol deviation that results in a signifi-
cant risk to the subject’s safety.
Subjects may voluntarily withdraw from the study for 
any reason at any time. They may be considered with-
drawn if they state an intention to withdraw, fail to return 
for visits or become lost to follow-up for any other reason. 
If a subject chooses to stop study treatment, the investi-
gator should encourage the subject to return for a last 
visit.
Before discontinuation, the subject should attend a 
visit with the same procedures as in the discharge visit. If 
premature withdrawal occurs for any reason, the investi-
gator must make all attempts to determine the primary 
reason for a subject’s premature withdrawal from the 
study and record this information on the study discharge 
case report form (CRF) page.
study assessments and visit schedule
study procedures/data acquisition
Ophthalmological examination
A standard slit-lamp ophthalmological examination will 
be performed in all visits in both eyes. The fundus will 
be observed after pupil dilation with eye drops. IOP will 
be measured prior to pupil dilation and always using the 
same type of equipment throughout the clinical trial. IOP 
will also be measured before and after the aflibercept 
injection. After the screening visit, the electronic CRF 
(eCRF) will only include data from the study eye.
Best-corrected visual acuity (BCVA)
BCVA will be evaluated in both eyes according to the 
ETDRS protocol in all visits.
Spectral domain optical coherence tomography (SD-OCT)
SD-OCT (macular acquisitions) will be performed in 
both eyes after pupil dilation, according to table 1 and 
must be sent to the Central Reading Centre for analysis. 
The study allows the use of Heidelberg Eye Explorer 
Spectralis SD-OCT, Cirrus HD OCT, Topcon 1000/2000/
Swept Source OCT Viewer and NAVIS-EX Nidek SD-OCT. 
The scanning protocol involves a macular cube acquisi-
tion, radial acquisition and linear acquisition. Operator 
and equipment certification is required before starting to 
acquire OCT examinations under the study protocol. The 
Central Reading Centre will provide a specific protocol 
detailing acquisition, export and submission procedures 
as well as instructions for prior certification activities.
Colour fundus photography (CFP), fluorescein angiography (FA) and 
indocyanine green angiography (ICGA)
Digital CFP, FA and ICGA of fields 1 and 2 at 30°/35° will 
be performed on both eyes after pupil dilation according 
to table 1 and must be sent to the Central Reading Centre 
for analysis.
ICGA will be performed at baseline, week 16 and week 
52 in all subjects. ICGA may be repeated at weeks 28 and 
40 if (1) there is a decline ≥5 letters on BCVA comparing 
to the highest BCVA during the study period and (2) 
there is evidence of macular fluid on SD-OCT. Photog-
rapher and equipment certification is required before 
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starting to acquire images under the study. The Central 
Reading Centre will provide a specific protocol detailing 
acquisition, export and submission procedures as well as 
instructions for prior certification activities.
Patient identification
Each subject will be uniquely identified by a subject iden-
tification code. This code is only used for study purposes. 
On signing the informed consent form, the subject will 
be identified by this subject identification code. This code 
will consist of a combination of three fixed digits ‘209’, 
plus three digits for the site number and two sequen-
tial digits for the subject number. For example, the first 
patient included in clinical sites number 001 and 015 will 
be 20900101 and 20901501, respectively. Once assigned 
to a subject, the subject identification code will not be 
reused.
Blinding/unblinding procedures and randomisation
The study medication (aflibercept) will be open label. 
Unblinding will not be applicable for aflibercept. The 
use of PDT will be double-masked. The investigator, 
sponsor, subject and monitor involved in reporting, 
obtaining and/or reviewing the clinical evaluations will 
not be aware of the treatment being administered in case 
of PDT. The double-blinding of the PDT will be main-
tained throughout the study. Only once all study data 
have been verified and the database locked, individual 
subjects will be unblinded. In the event that an emer-
gency blind break is required, the treatment that the 
subject has received will be provided to the investigator. 
In case a suspected unexpected serious adverse reaction 
(SUSAR) occurs during the study, the sponsor’s phar-
macovigilance department (or designee) will be able to 
break the blind in order to comply with legal expedited 
reporting requirements.
The randomisation will be centrally generated and 
assigned to eligible subjects/eyes in order to balance the 
subject allocation between treatment arms. This will take 
place at week 16, where all patients will be randomised in 
a 1:1 ratio into one of the following groups:
 ► Group 1: Intravitreal injection of aflibercept 
2 mg/0.05 mL T&E + vPDT
Figure 1 Diagram flow of the study. IVA, intravitreal aflibercept; OCT, optical coherence tomography; PDT, photodynamic 
therapy; vPDT, verteporfin photodynamic therapy; sPDT, sham photodynamic therapy; T&E, treat and extend.
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 ► Group 2: Intravitreal injection of aflibercept 
2 mg/0.05 mL T&E + sPDT
ICGA is mandatory at week 16 and will be the basis to 
differentiate patients with active and patients with inactive 
polyps. Every subject will receive an intravitreal injection 
of aflibercept, despite the treatment group or the polyp 
activity. However, PDT (vPDT and sPDT) will only be 
applied in the presence of active polyps confirmed by 
ICGA. This means that both groups will include patients 
who will and patients who will not undergo PDT at week 
16 (figure 1).
Screening failures
Subjects discontinuing prior to the first injection of 
aflibercept are considered screening failures. All data 
collected during the screening visit will be registered as 
well as the reason for not starting treatment.
Study completion
Subjects who successfully complete the study through 
week 52 will be considered to have completed the study 
for data analysis.
Early study termination
The study can be terminated at any time by the sponsor, 
the competent authorities (CAs) or by the Institutional 
Review Board/Independent Ethics Committees (IRB/
IEC). Should this be necessary, subjects should be seen as 
soon as possible and treated as described for a prematurely 
withdrawn subject. The investigator may be informed of 
additional procedures to be followed in order to assure 
that adequate consideration is given to the protection of 
the subjects’ interests.
treatment
Investigational and control treatment
Treatment arms
If a subject’s eligibility is confirmed, the patient will receive 
one intravitreal injection of aflibercept 2 mg/0.05 mL per 
month for three consecutive months (weeks 0, 4 and 8)—
loading phase (figure 1).
Subjects will return for treatment at week 16. At this 
point, they will be randomised in a 1:1 ratio into one of 
the following groups:
 ► Group 1: Intravitreal injection of aflibercept 
2 mg/0.05 mL T&E + vPDT
 ► Group 2: Intravitreal injection of aflibercept 
2 mg/0.05 mL T&E + sPDT
Note:
 ► At week 16, all subjects receive IVA.
 ► PDT (vPDT or sPDT) will only be used in the pres-
ence of active polyps on ICGA. Treatment will be 
performed with ICGA-guided standard fluence vPDT, 
as described by the Treatment of Age-related macu-
lar degeneration with Photodynamic therapy (TAP) 
study group17 (verteporfin dose of 6 mg/m2 of body 
surface; light dose of 50 J/cm2; exposure time of 83 s). 
The irradiated area will depend on the lesion’s GLD 
measured on ICGA, plus an extra 500 µm margin on 
each side (1 mm extra).
 ► The need for further PDT will again be assessed by 
ICGA on weeks 28 and 40 if (1) there is a decline ≥5 
letters on BCVA comparing to the highest BCVA dur-
ing the study period and 2) there is evidence of mac-
ular fluid on SD-OCT. If ICGA confirms the presence 
of active polyps, PDT will be used, within 1 week after 
the intravitreal injection of aflibercept.
 ► After week 16, the frequency of injections will depend 
on the presence of macular fluid (6 mm central) as-
sessed by SD-OCT. When macular fluid is confirmed 
by SD-OCT, the interval between injections will de-
crease 2 weeks, up to a minimum of 6 weeks. On the 
other hand, if macular fluid is not present on SD-OCT, 
the interval between visits will increase 2 weeks, up to 
a maximum of 12 weeks.
 ► Since the frequency of study visits will depend on the 
presence of macular fluid on SD-OCT at weeks 16, 
28 and 40, the number of visits per patient will range 
from 11 to 12 visits.
Patient treatment assignment
At week 0, subjects who fulfil all the eligibility criteria will 
start treatment with aflibercept (weeks 0, 4 and 8). At 
week 16, subjects will be given a randomisation number. 
This number assigns them to one of the treatment arms 
(vPDT or sPDT). The randomisation numbers will be 
centrally generated in order to ensure that treatment 
assignment is unbiased. A randomisation list will be 
produced by the coordinating centre using a validated 
system that randomly assigns treatment arms to randomi-
sation numbers in the specified ratio 1:1 and according 
to stratification by polyp activity (indicated by ICGA). In 
case of dropout, previously randomised subjects will not 
be replaced.
Study treatment
Study medication
This study will include the following study medication:
 ► 40 mg/mL aflibercept (labelled Eylea)
Dosage form, packaging and labelling
Eylea 40 mg/mL solution is formulated as a sterile solu-
tion for injection in a phial. Each phial contains 100 µL, 
equivalent to 4 mg aflibercept. This provides a usable 
amount to deliver a single dose of 50 µL containing 2 mg 
aflibercept. Aflibercept must be stored according to 
the label instructions contained on the summary of the 
product characteristics (SmPC) and it must be kept in a 
secure locked facility. Since marketed Eylea will be used, 
each box will be labelled with the appropriate informa-
tion stating that the medication is for use in this clinical 
trial only. Medication labels will comply with the legal 
requirements and be printed in the local language. The 
storage conditions for study medication will be described 
on the medication label.
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Dispensing
Study medication will be dispensed to the subjects 
according to this protocol and with the given instructions.
Storage and drug accountability
The study medication will be stored in accordance with 
ICH-good clinical practice (GCP) and SmPC. The study 
medication should be received by the principal investi-
gator or designee at the clinical site, handled and stored 
safely and properly and kept in a secure location to which 
only the principal investigator and designated assistants 
have access.
In the clinical sites, a temperature log will be main-
tained, documenting appropriate medication storage 
conditions and will be made available for the monitor to 
inspect.
During the study, the principal investigator or designee 
will conduct an inventory of the study medication and 
maintain records of the study medication dispensing 
for each subject. This record will be made available to 
the monitor for the purpose of verifying the accounting 
of medication. Any discrepancies and/or deficiencies 
between the observed disposition and the written account 
will be recorded along with an explanation. The principal 
investigator will also ensure that the study medication will 
not be used in any unauthorised manner.
Photodynamic therapy (PDT)
 ► 2 mg/mL verteporfin (labelled Visudyne)
 ► 5% dextrose solution (sPDT)
Verteporfin will be used for the vPDT while the 5% 
dextrose solution will be used for the sPDT. Each clin-
ical site will purchase verteporfin to perform PDT to its 
subjects, according to the current package labelling and 
SmPC.
Masking
PDT will be double-masked; therefore, each member 
of the investigational team must remain either masked 
or unmasked to the treatment assigned for each subject 
along the conduction of the study in order to avoid bias 
(table 2).
Masked roles
The masked investigational team will perform all 
procedures, except the treatment with PDT and the 
accountability/handling of PDT medication. An 
independent monitor will be responsible for pharmacy 
site visits and will be unmasked to treatment. Further, the 
subjects will also remain masked along the conduction.
Under no circumstances the unmasked study pharma-
cist and/or study nurse will perform efficacy and safety 
procedures.
Unmasked roles
Only the pharmacist and/or the study nurse who performs 
the drug accountability and/or prepares the PDT treat-
ment will be unmasked. They will not have any other role 
in the study. The verteporfin infusion and the sham infu-
sion will be covered by foil paper or other material so that 
the investigator is not aware if the treatment is vPDT or 
sPDT. Independent study personnel responsible for drug 
supply and unmasked monitors who are not involved in 
the conduction of the study can also be unmasked.
Instructions for prescribing and performing/taking the study 
treatments
After the mandatory loading phase in weeks 0, 4 and 8, 
the frequency of the injections will depend on the pres-
ence/absence of macular fluid (6 mm central) assessed by 
SD-OCT at weeks 16, 28 and 40.
Permitted study treatments adjustments and interruptions
Study medication dose adjustments are not permitted.
Treatment exposure and compliance
The investigator should promote compliance by 
informing the subject of the importance of attending 
each scheduled visit in order to monitor the subject’s 
safety, efficacy and the validity of the study. The subject 
should be instructed to contact the investigator if he/she 
is unable to attend the study visits.
Rescue treatments
If a subject needs a rescue treatment different from 
the study treatments due to severe vision loss (15 or 
more letters of BCVA compared with baseline) or safety 
reasons, he/she must be withdrawn from the study before 
treatment is performed.
Concomitant treatment
Any concomitant medication used by a subject from the 
date of enrolment (screening visit) until the conclusion 
of the study participation (except for routine medications 
given for ocular procedures required by the protocol, ie, 
fluorescein, indocyanine, dilating drops, topical anti-
biotic, topical anaesthetic) should be recorded on the 
concomitant medication CRF page including start and 
stop dates and indication.
The following treatments are not allowed during the 
study:
 ► Anti-VEGF therapy (pegaptanib sodium, anecortave 
acetate, bevacizumab, ranibizumab and so on) or in-
travitreal corticosteroids in the study eye.
 ► Systemic medications known to be toxic to the lens, 
retina or optic nerve, including deferoxamine, chlo-
Table 2 Masked and unmasked roles at the clinical site
Masked/unmasked Investigational team
Masked Principal investigator
Investigator
Study coordinator
Technicians
Unmasked Study nurse
Pharmacist
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roquine/hydroxychloroquine (plaquenil), tamox-
ifen, phenothiazines and ethambutol.
If the fellow-eye needs treatment for wet AMD 
(including PCV), subjects can be treated with any medi-
cation according to clinical practice and continue in the 
study.
The investigator should instruct the subject to notify 
the investigator about any new medications he/she 
takes after the start of the study. All medications (other 
than study medication and routine medications given 
for ocular procedures required by the protocol) and 
significant non-drug therapies must be recorded on the 
concomitant medication CRF page.
Emergency unblinding
In case of a SUSAR, the treatment code (PDT versus 
sPDT) will usually be unblinded. In case of other medical 
emergency or other situation in which the knowledge 
of a subject’s assigned treatment is essential to medical 
management of the subject, the investigator may unmask 
the treatment group of the subject.
Each unblinding has to be reported to the sponsor and 
also the reason for unblinding. Preferably, the investi-
gator should inform the sponsor before the unblinding.
Unblinding will lead to the disqualification of the 
subject for the statistical analysis.
study completion and poststudy treatment
The end of the study corresponds to the last visit of the 
last subject in the last clinical site. Subjects completing 
the study will be treated at hospital or private clinic 
according to accepted medical practice. The investigator 
should also provide follow-up medical care for all subjects 
who are prematurely withdrawn from the study, or must 
refer them for appropriate ongoing care.
Efficacy assessments
Parameters
Efficacy will be assessed based on the following parame-
ters: BCVA, SD-OCT and polyp regression.
Monitoring
Efficacy monitoring will be assessed through the efficacy 
parameters progression from baseline to week 52.
A data management plan and monitoring plan (MP) 
will be elaborated.
safety assessments
Parameters
Safety parameters will include assessment of IOP, AEs (see 
Section ‘Adverse events’) and SAEs (see Section ‘Serious 
adverse event reporting and follow-up’).
Monitoring
Safety assessment will consist of measuring IOP and moni-
toring/recording all safety parameters from baseline to 
week 52. A MP of the clinical trial will be elaborated to list 
in detail how safety monitoring will be conducted.
Adverse events
An AE is any unfavourable and unintended sign 
(eg, including an abnormal laboratory finding), symptom 
or disease temporally associated with the use of an investi-
gational medicinal product and/or any study procedure, 
whether or not considered related to the investigational 
medicinal product.
The occurrence of AEs should be sought by non-direc-
tive questioning of the subject at each visit during the 
study. AEs may also be detected when they are volun-
tarily reported by the subject during or between visits 
or through physical examination, laboratory testing, 
or other assessments. All AEs must be recorded on the 
adverse event log of the CRF. All AEs will be collected 
from the first day until 30 days after discontinuation/
completion of study participation even if the event is not 
considered to be related to the study medication.
Medical conditions/diseases present before starting 
the study are only considered AEs if they worsen after 
starting the study (exacerbation). Abnormal laboratory 
values or test results constitute AEs only if the investi-
gator considers them clinically significant and requiring 
treatment adjustment, transitory or permanent study 
medication discontinuation or any other interventional 
measure or diagnostic evaluation of subject risk. They 
should be investigated and monitored appropriately.
Serious adverse events
Definitions
Serious adverse event (SAE) and serious adverse reaction 
(SAR)
Any untoward medical occurrence or effect that, at any 
dose:
 ► results in death,
 ► is life threatening,
 ► requires hospitalisation or prolongation of existing 
hospitalisation,
 ► results in persistent or significant disability or incapac-
ity,
 ► is a congenital anomaly or birth defect,
 ► is an important medical event.
Serious unexpected suspected adverse reaction 
(SUSAR)
Any SAR with a nature or severity that is not described 
in the Reference Safety Information (ie, the SmPC for an 
authorised product).
The following AE do not need to be managed as serious:
 ► Hospitalisation for routine treatment or monitoring 
of the studied indication not associated with any dete-
rioration in condition.
 ► Hospitalisation for elective or preplanned treatment 
for a pre-existing condition that is unrelated to the in-
dication under study and has not worsened since the 
start of the study.
 ► Treatment on an emergency outpatient basis for an 
event not fulfilling any of the definitions of a SAE giv-
en above and not resulting in hospital admission.
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The other SAEs should be reported as specified below.
Reporting and follow-up
In case of a SAE, the investigator has to immediately report 
to the sponsor or designee all SAEs with the exception 
of those that are identified as not requiring immediate 
reporting in the protocol.
If a SAE occurs, the investigator must fill in a SAE form 
within 24 hours of learning of its occurrence. This is also 
applicable to any SAE that occurs within 30 days after 
study medication discontinuation.
The sponsor or designee is responsible for submit-
ting to CAs and Ethic Committees all SUSARs collected 
during the study, following the procedure and time frame 
described in the legislation currently in force.
The sponsor or designee will also report, in an expe-
dited manner, any other safety information that could 
modify the benefit-risk balance of the investigational 
drug.
Pregnancy
Women of childbearing potential who are not using 
adequate birth control will be excluded from the study. 
Nevertheless, any pregnancy that occurs during the 
study, although not itself an SAE, should be recorded 
and reported by the investigator to the sponsor within 
24 hours of learning of its occurrence to facilitate outcome 
follow-up.
Abortion, whether it is accidental, therapeutic or spon-
taneous, should be reported as an SAE. Similarly, any 
congenital anomaly/birth defect in a child born to a 
subject exposed to the investigational treatment should 
be reported as an SAE.
Female subjects must be instructed to stop taking 
the study medication and immediately inform the 
investigator if becoming pregnant during the study. Preg-
nancies beginning within 30 days after the completion of 
the last dose of study medication must also be reported 
to the investigator. The investigator should counsel the 
subject, discussing the risks of continuing with the preg-
nancy and the possible effects on the fetus. Monitoring 
of the subject should continue until conclusion of the 
pregnancy.
Pregnancy occurring in the partner of a subject partic-
ipating in the study should also be reported to the 
investigator and sponsor. Pregnancy follow-up should be 
recorded on the same form and should include an assess-
ment of the possible relationship to the study medication 
of any pregnancy outcome.
Annual safety report
Annually, the sponsor or designee will prepare a Develop-
ment Safety Update Report (DSUR) that will include all 
SAEs and SUSARs collected during the reporting period. 
The sponsor will submit the DSUR to CAs and involved 
Ethic Committees, following the time frame established 
in the legislation currently in force.
data analysis
Sample size
Fifty patients, approximately 25 from each country 
(Portugal and Spain), will be considered for this study. 
Since it is a pilot study, no sample size estimation was 
performed.
Population(s) for analysis
The intent-to-treat (ITT) and per-protocol (PP) popula-
tions will be considered for analysis. The ITT population 
will be used for the primary efficacy analysis. In a second 
analysis, the PP population will be used. If the ITT and 
the PP analyses yield the same results, the PP will provide 
supportive evidence of the magnitude of the treatment 
effect among subjects with different treatment regimens. 
If the results of the two methods differ, exploratory anal-
yses will be performed to evaluate the factors that may 
contribute to the differences.
Demographic and baseline data
During the screening visit, for each subject, the following 
information will be recorded by the investigator:
 ► Demography: date of birth, gender, race
 ► Medical history (ocular and non-ocular)
 ► Vital signs
 ► Physical examination
 ► Slit lamp examination
 ► Fundus examination
 ► IOP
 ► BCVA
Grading results will be recorded by the Central Reading 
Centre for the following procedures:
 ► SD-OCT
 ► CFP
 ► FA
 ► ICGA
Statistical analysis
Continuous variables will be summarised using the 
following statistics: number (non-missing sample 
size), mean, SD, median, IQR, first and third quar-
tiles, minimum and maximum. The number of missing 
observations will also be reported. The frequency and 
percentages (based on the non-missing sample size) 
of observed levels will be reported for all categorical 
measures. The number of missing observations will also 
be reported.
For the primary efficacy analysis following the ITT 
principle, the full analysis set that include all randomised 
subjects at week 16 will be used. Missing data will be 
treated by using last observation carried forward (LOCF).
The safety analysis set will include all subjects who 
receive any IVA.
Statistical analyses will be performed with STATA 
version 12.1 (StataCorp, College Station, Texas, USA).
All statistical issues including variables description, 
tables’ contents and statistical methods will be detailed 
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in the statistical analysis plan that will be finalised before 
study database lock.
Primary and secondary variables
Primary variables
The primary variables will be defined as:
1. Change in BCVA from Baseline to week 52, that is, 
BCVA at week 52 minus BCVA at Baseline
2. Polyp regression at week 52 (assessed by ICGA)
Secondary variables
The secondary variables will be defined as:
1. Change in BCVA over time
2. Change in BCVA at week 16
3. BCVA gain ≥5, 10 or 15 letters at week 52
4. BCVA loss ≥5, 10, 15 or 30 letters at week 52
5. BCVA maintenance at week 52 (BCVA change from 
baseline between −5 and +5 letters, exclusively)
6. Polyp regression at week 16, assessed by ICGA
7. Complete polyp regression at week 52, assessed by 
ICGA
8. Complete polyp regression at week 16, assessed by 
ICGA
9. Presence of active polyp at week 52, assessed by ICGA
10. Presence of active polyp at week 16, assessed by ICGA
11. Presence of leakage based on fluorescein angiography 
(FA) at week 52
12. Change in the subfield CRT over time (assessed by 
spectral domain optical coherence tomography (SD-
OCT))
13. Presence of fluid assessed on SD-OCT at week 52
14. Total number of treatments with aflibercept
15. Total number of treatments with verteporfin PDT
16. Frequency and severity of ocular and non-ocular AEs 
over time
Morphological variables assessed by the Central 
Reading Centre (based on SD-OCT, CFP, FA and ICGA) 
will be defined in the SAP.
Statistical hypothesis, model and methods
A descriptive analysis will be conducted to all study vari-
ables. Continuous variables will be summarised using 
the following statistics: number (non-missing sample 
size), mean, SD, median, IQR, first and third quar-
tiles, minimum and maximum. The number of missing 
observations will also be reported. The frequency and 
percentages (based on the non-missing sample size) 
of observed levels will be reported for all categorical 
measures. The number of missing observations will also 
be reported.
Demographic and baseline data will be described using 
the descriptive measures defined above and according to 
each variable type.
Two analyses will be performed for the primary objec-
tive considering the two primary outcomes, change in 
BCVA from baseline to week 52 and polyp regression at 
week 52.
A two-way factorial analysis of variance (ANOVA) with 
treatment group and need of PDT as fixed factors will be 
used to assess the difference between treatments, afliber-
cept associated with vPDT and aflibercept associated with 
sPDT, for the change in BCVA from baseline to week 52. 
The following null (H0) and alternative (H1) hypotheses 
will be considered:
 ► H0: µ1=µ2
 ► H1: µ1≠µ2
where µ1 is the mean change in ETDRS letter score 
from baseline to week 52 in treatment group afliber-
cept associated with vPDT and µ2 is the mean change in 
ETDRS letter score from baseline to week 52 in treatment 
group aflibercept associated with sPDT.
For the polyp regression at week 52, a two-way facto-
rial ANOVA with treatment group and need of PDT as 
fixed factors will also be used to assess the difference 
between treatments, aflibercept associated with vPDT 
and aflibercept associated with sPDT. The following 
null (H0) and alternative (H1) hypotheses will be 
considered:
 ► H0: µ’1=µ’2
 ► H1: µ’1≠µ’2
where µ’1 is the mean difference of the total area of 
polyps from baseline to week 52 in treatment group 
aflibercept associated with vPDT and µ’2 is the mean 
difference of the total area of polyps from baseline to 
week 52 in treatment group aflibercept associated with 
sPDT.
Statistically significant results for the primary endpoints 
will be considered if one of the tests reached a significant 
level of 0.025.
For the secondary objectives, an exploratory analysis 
will be performed, particularly for the evaluation of the 
potential benefit, based on the secondary outcomes, of 
vPDT compared with sPDT in patients with PCV treated 
with aflibercept under a T&E regimen.
The different secondary variables will be analysed in 
both treatment groups.
The number of injections will be tabulated separately 
for subjects that received aflibercept and for subjects that 
received aflibercept associated with PDT in both treat-
ment groups.
The proportion of subjects who never needed PDT will 
be analysed for both treatment groups.
Due to the small sample size, non-parametric tests may 
be used.
All statistical issues including variables description, 
tables’ contents and statistical methods will be detailed in 
the SAP that will be finalised before study database lock.
Levels of significance/adjustments
The significance level assumed for the final analysis will 
be adjusted according to the analyses performed. For the 
primary analysis, the p value will be adjusted to 0.025 for 
the two primary variables.
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Missing values/censoring/discontinuations/outliers
Due to the small sample size, the LOCF method will be 
used.
Interim analysis
No interim analysis is planned. If during the study an 
interim analysis is required, due to safety, efficacy or only 
for monitoring purposes, this analysis will be masked for 
the PDT treatment and described in the SAP.
Reporting deviations from the planned statistical analysis
Deviations from the planned statistical analysis will be 
reported and justified in the final study report.
Safety analysis
For the safety analysis, only treatment-emergent AEs will 
be considered (eg, AEs with onset after the start of the 
particular treatment or AEs present prior to the treatment 
but with increased severity). The number and percentage 
of subjects reporting AEs will be presented. The IOP 
measurements will be analysed descriptively including 
changes from baseline.
Access to source data/documents
Before study initiation or at the baseline visit, the study 
documents, including the protocol and CRF will be 
reviewed with the investigators and their staff.
During the study, the following parameters will be 
checked (in accordance with the MP): (1) completeness 
of subject records; (2) accuracy of entries on the CRF; (3) 
adherence to the protocol and to good clinical practices; 
(4) progress of the enrolment; (5) storage, dispensing 
and accounting of the study medication according to 
specifications.
The principal investigator should give the monitor 
access to the relevant source documents (relevant to 
check the compliance of the clinical protocol) to confirm 
their consistency with the CRF entries. Monitoring stan-
dards require verification of the presence of informed 
consent, adherence to the inclusion/exclusion criteria, 
report of SAEs and the recording of data that will be 
used for efficacy and safety variables. No information in 
source documents about the identity of the subjects will 
be disclosed.
Quality control and quality assurance
Designated investigator staff must enter the information 
required by the protocol into the CRF.
The principal investigator should ensure that 
the subject’s anonymity is maintained throughout 
the course of the study. In particular, the principal 
investigator should keep an enrolment log with confi-
dential identifying information that corresponds to 
the subject numbers. All documents submitted from 
the clinical sites will identify the subject exclusively by 
number. No other personally identifying information 
should be transmitted.
Monitors will review the CRF for completeness and 
accuracy and instruct clinical site personnel to make any 
required corrections or additions. Queries are sent to the 
clinical site. Designated clinical site staff is required to 
respond to the query and clinical site will make the neces-
sary changes to the data.
Data clarifications and/or additions are documented 
and are part of each subject’s CRF. After these actions 
have been completed and the database has been declared 
to be complete and accurate, it will be locked and data 
will be made available for data analysis.
Ethics and dissemination
Ethical considerations
Regulatory and ethical compliance
This study was designed and shall be implemented 
and reported in accordance with the ICH Harmon-
ised Tripartite Guidelines for Good Clinical Practice, 
with applicable local regulations (including European 
Directive No 2001/20, US Code of Federal Regula-
tions Title 21 and Japanese Ministry of Health, Labour 
and Welfare) and with the ethical principles laid down 
in the Declaration of Helsinki. The study received 
approval from the IRB— Comissão de Ética para a Inves-
tigação Clínica (CEIC), the Portuguese National Ethics 
Committee for Clinical Research (http://www. ceic. 
pt) and Comité Ético de investigación Clínica del Hospital 
Universitari de Bellvitge.
Informed consent procedures
Subjects should only perform any of the study proce-
dures after providing written (witnessed, where 
required by law or regulation) IRB/IEC approved 
informed consent or, if incapable of doing so, after 
such consent has been provided by a legally accept-
able representative of the subject. In cases where the 
subject’s representative gives consent, the subject 
should be informed about the study to the extent 
possible given his/her understanding. If the subject 
is capable of doing so, he/she should indicate 
assent by personally signing and dating the written 
informed consent document or a separate assent 
form. The process of obtaining informed consent 
should be documented in the subject source docu-
ments.
The investigator must ensure that each subject is fully 
informed about the nature and objective of the study and 
possible risks associated with participation. Subject should 
indicate assent to participate in the study by personally 
signing and dating the written informed consent form. 
The investigator will retain the original of each subject’s 
signed informed consent form and he will give a copy to 
the subject.
Amendments may require informed consent form and/
or other study-related material revision. If the informed 
consent form is revised, all subjects currently enrolled 
in the study must sign the approved, revised informed 
consent form.
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Responsibilities of the investigator
The protocol and the informed consent form must 
be reviewed and approved by the regulatory authori-
ties before study start. The protocol must be reviewed 
and approved by the CA and IRB/IEC and informed 
consent form must be reviewed and approved IRB/IEC 
and CA if applicable. A signed and dated statement 
that the protocol and informed consent have been 
approved by the national regulatory authorities must 
be given to the sponsor before study initiation. Prior 
to the start of the study, the principal investigator is 
required to sign a protocol signature page confirming 
his/her agreement to conduct the study in accordance 
with these documents and all of the instructions and 
procedures found in this protocol and to give access 
to all relevant data and records to study monitors, 
auditors and  regulatory authorities as required. If an 
inspection of the clinical site is requested by a regu-
latory authorities, the investigator must inform the 
sponsor immediately that this request has been made.
The principal investigator and all clinical study staff 
will conduct the clinical study in compliance with the 
protocol. The principal investigator will ensure that all 
personnel involved in the conduct of the study are qual-
ified to perform their assigned responsibilities through 
relevant education, training and experience.
Data handling and record keeping
The principal investigator must maintain up-to-date 
source documents for each subject, consisting of case 
and visit notes (hospital or clinic medical records) 
containing demographic and medical information, 
laboratory data and the results of any other tests or 
assessments. All information on CRFs must be trace-
able to these source documents in the subject’s file. 
The investigator must also keep the original informed 
consent form signed by the subject.
The principal investigator must keep study records and 
source documents during at least 10 years according to 
internal procedure of the sponsor or superior to comply 
with national law.
If for any reason the principal investigator withdraws 
from the responsibility of keeping the study records, 
custody must be transferred to the sponsor.
Financing and insurance
This is an Investigator Driven Clinical Trial. Financial 
support will be given to the clinical sites according to 
the Clinical Trial Agreement that will be signed with the 
sponsor to perform the clinical study.
As required by the national law, the sponsor will provide 
insurance for the clinical trial to cover any subject injuries 
related with the clinical trial procedures and/or treat-
ments.
Publication policy
On study completion and finalisation of the study report, 
the results of this trial will be submitted for publication 
at a peer-reviewed journal. Also, the study results will be 
presented at local and international congresses with the 
intention to share the new scientific data with our peers. 
The publication policy will be described in the Clinical 
Trial Agreement.
Protocol
Protocol adherence
Investigators ascertain that they will apply due diligence 
to avoid protocol deviations. If the investigator believes 
that a protocol deviation would improve the conduct 
of the study, this must be considered a protocol amend-
ment, and unless such an amendment is agreed on by the 
sponsor and approved by the CA and IRB/IEC, it cannot 
be implemented.
Protocol amendments
Any change or addition to the protocol can only be 
made in a written protocol amendment that must 
be approved by the sponsor, the CA and IRB/IEC. 
Only amendments that are required for subject safety 
may be implemented prior to regulatory authori-
ties approval. Notwithstanding the need for approval 
of formal protocol amendments, the investigator is 
expected to take any immediate action required for 
the safety of any subject included in this study, even if 
this action represents a deviation from the protocol. 
In such cases, the sponsor should be notified of 
this action and the regulatory authorities should be 
informed within 10 working days.
Amendments may require informed consent form and/
or other study-related material revision. If the informed 
consent form is revised, all subjects currently enrolled 
in the study must sign the approved, revised informed 
consent form.
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